Janus kinase-1 and Janus kinase-2 inhibitors for treating myelofibrosis

Martí‐Carvajal, Arturo J; Cardona, Andrés Felipe; Anand, Vidhu; Solà, Iván

doi:10.1002/14651858.cd010298

Cited by 3 publications

(2 citation statements)

References 67 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…3 Approximately 8%-20% of patients with MF eventually transform into acute myeloid leukaemia and consequently have an even shorter survival. [4][5][6] Historically, available treatment options for MF have been symptomatic with limited or no disease modifying potential. In a Swedish population-based study, Hultkrantz et al 2 described improved survival outcomes in MPN patients over the last decades; however, the improvement was less pronounced after the calendar year 2000 and confined to patients with PV and ET, suggesting dismal outcomes with current treatment options for MF in clinical practice.…”

mentioning

confidence: 99%

Survival outcomes in myelofibrosis patients treated with ruxolitinib: A population‐based cohort study in Sweden and Norway

Schain

Vágó

Song³

et al. 2019

European J of Haematology

View full text Add to dashboard Cite

ObjectiveTo estimate survival in Swedish and Norwegian myelofibrosis (MF) patients who received ruxolitinib.MethodsSwedish and Norwegian patients with MF diagnosis in the National Cancer Registries (Sweden: 2001‐2015; Norway: 2002‐2016) and ≥1 record of ruxolitinib in the Prescribed Drug Registries (2013‐2017) were included. Patients were followed from ruxolitinib initiation until death or end of follow‐up; those who discontinued ruxolitinib were followed from ruxolitinib discontinuation. Relative survival (RS) and excess mortality rate ratios (EMRRs) were calculated vs a matched general population. Average loss in life expectancy (LEL) was predicted using flexible parametric models.ResultsAmong patients who initiated ruxolitinib (n = 190), 1‐ and 4‐year RS were 0.80 (95% confidence interval [CI]: 0.74, 0.86) and 0.52 (95% CI: 0.42, 0.64), respectively, and LEL was 11 years. EMRR was greater in patients aged >70 vs <60 years (3.16; 95% CI: 1.34‐7.40). Among patients who discontinued ruxolitinib (n = 71), median RS was 16.0 months (95% CI: 6.3, NE), and LEL was 12 years. After ruxolitinib treatment discontinuation, Swedish patients (n = 37) received glucocorticoids, hydroxyurea, busulfan, danazol and lenalidomide.ConclusionSwedish and Norwegian MF patients who discontinued ruxolitinib had dismal survival outcomes and limited subsequent treatment options, highlighting the need for improved therapies.

show abstract

mentioning

confidence: 99%

Survival outcomes in myelofibrosis patients treated with ruxolitinib: A population‐based cohort study in Sweden and Norway

Schain

Vágó

Song³

et al. 2019

European J of Haematology

View full text Add to dashboard Cite

show abstract

“…The OS benefit was further investigated in a Cochrane systematic review evaluating the efficacy of ruxolitinib, which concludes that there is insufficient evidence to draw conclusions on survival benefit compared to placebo or BAT. 20 Accordingly, we must interpret the OS benefit noted in the COMFORT-I and II trials with caution, and this remains a topic of debate.…”

Section: Ruxolitinibmentioning

confidence: 99%